Clinical Experience with SERPINA1 DNA Sequencing to Detect Alpha-1 Antitrypsin Deficiency

Diagnostic methods for AATD usually follow a multistep testing algorithm, including measuring serum alpha-1 antitrypsin levels, targeted genotyping toward the most common mutations, and phenotyping protease inhibitor with isoelectric focusing of serum alpha-1 antitrypsin (6, 7). Furthermore, each st...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the American Thoracic Society Jg. 15; H. 2; S. 266 - 268
Hauptverfasser: Maltais, François, Gaudreault, Nathalie, Racine, Christine, Thériault, Sébastien, Bossé, Yohan
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States American Thoracic Society 01.02.2018
Schlagworte:
Algorithms
Clinical medicine
Deoxyribonucleic acid
Disease
DNA
Emphysema
Family medical history
Genetic disorders
Mutation
Studies
Canada
Quebec Canada
ISSN:2329-6933, 2325-6621, 2325-6621
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Diagnostic methods for AATD usually follow a multistep testing algorithm, including measuring serum alpha-1 antitrypsin levels, targeted genotyping toward the most common mutations, and phenotyping protease inhibitor with isoelectric focusing of serum alpha-1 antitrypsin (6, 7). Furthermore, each step has its own intrinsic limitations, creating further uncertainty in the interpretation of the results: 1) serum alpha-1 antitrypsin levels may be falsely elevated during acute inflammatory conditions (8); 2) commercially available genotyping tests are testing only the most common mutations, a major limitation considering that over 250 gene variants have been reported; and 3) protease inhibitor phenotyping only provides presumptive genotypes and characterizes a limited number of protein phenotypes. Discussion From this experience, we suggest a diagnostic scheme based on alpha-1 antitrypsin level, alone or supplemented with SERPINA1 DNA sequencing, depending on the presence or absence of clinical features associated with AATD (emphysema before 45 yr of age, predominant basal emphysema, positive family history, and associated liver disease or bronchiectasis; Figure 1). [...]DNA sequencing reveals the exact mechanism of the deficit, serves as a confirmatory diagnostic tool because the levels are not always reliable due to their intrinsic variability, and is necessary to investigate family members of the index case (7).
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Correspondence-1
ISSN:2329-6933
2325-6621
2325-6621
DOI:10.1513/AnnalsATS.201708-694RL